Why the study?
Chronic HIV infection and antiretroviral therapy (ART) are major causes of cardiovascular diseases and mortality in HIV patients, prompting evaluation of the effect of ART regimens on CVD risk markers.
Does antiretroviral therapy increase cardiovascular risk markers (CIMT and hsCRP) in HIV-infected patients?
Does antiretroviral therapy increase cardiovascular risk markers (CIMT and hsCRP) in HIV-infected patients?
Antiretroviral therapy, especially second-line regimens, is associated with increased surrogate markers of cardiovascular risk (CIMT and hsCRP) in people living with HIV.
ART effects on CVD markers in HIV are hypothesis-generating; leaves open need for randomized validation.
Introduction: Chronic HIV infection and antiretroviral therapy (ART) are the major causes of cardiovascular diseases (CVDs) and mortality in HIV patients. This study was conducted to look upon the effect of ART on CVD risk markers in patients on different ART regimens and ART-naïve patients. Methods: It was a cross-sectional, observational study done on 120 HIV-infected patients. CV risk markers were assessed and correlated with disease-specific factors within individual subgroups differentiated as Group A (ART naïve), Group B (first-line ART), and Group C (second-line ART). Carotid intimal medial thickness (CIMT) and high-sensitivity C reactive protein (hsCRP) were done to classify cases as having CVD. Results: CVD risk parameters were found to be significantly higher in cases on ART, as compared to ART-naïve cases. The mean CIMT among cases in Group C, Group B, and Group A was 0.072 ± 0.01 cm, 0.063 ± 0.01 cm, and 0.055 ± 0.01 cm, respectively ( P < 0.01). 95%, 65% and 25% cases in Group C, Group B, and Group A, respectively, had high CIMT (>0.06 cm) and were seen to be directly correlated with disease-related factors, i.e., duration of disease and ART, type of ART, and low CD4 cell counts. hsCRP was significantly increased in 65 out of total 120 cases. The mean hsCRP in Group A, Group B, and Group C was 3.69 ± 3.37, 4.21 ± 3.4, and 5.72 ± 3.54 mg/L, respectively ( P < 0.01), which corresponds to the high risk of CVD. Conclusion: CVD risk parameters of CIMT and hsCRP are seen to be higher in patients on ART than ART-naive subjects.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: